Navigation Links
La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial

SAN DIEGO, March 20, 2007 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company today announced updated interim antibody reduction data for the Phase 3 trial of Riquent(R) (abetimus sodium), its drug candidate for systemic lupus erythematosus ("lupus" or "SLE"). The updated analyses reinforce the previous conclusion that there is a definitive and significant dose response between the 100 mg, 300 mg and 900 mg doses of Riquent compared with placebo (p=0.0001). These interim data were initially announced March 8, 2007.

Dose Dependent Antibody Reduction

The minor changes to the data show a greater reduction from baseline in antibody levels in patients treated with Riquent. The median percent reductions were 100 mg: 18%; 300 mg: 28%; 900 mg: 46% at week 8. In parallel, there was less of an increase above baseline in the antibody levels for the placebo group. As a result, the reductions in median antibody levels between the Riquent treatment groups and the placebo treatment group at week 8 were 100 mg: 30%; 300 mg: 40%; 900 mg: 58% (p=0.0032, p<0.0001, p<0.0001 respectively).

Approximately three times as many patients treated with 900 mg of Riquent (42%) had at least a 50% or greater antibody reduction at week 8 compared with patients treated with 100 mg (13%). Patients reached their maximum reduction after four weeks of treatment at which time separation between doses was also seen.

The analyses assessed the impact of treatment with Riquent on reducing antibodies to dsDNA in 101 patients by measuring the percent of antibody reduction from baseline compared with placebo following weekly treatment with 100 mg, 300 mg or 900 mg of Riquent or placebo. All demographics and baseline characteristics were comparable across dosing groups and there were 16 to 30 patients per treatment group.

Consistent Antibody Reductions

Published data from earlier La Jolla studies indicated tha
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:5/23/2013)... Conn. , May 23, 2013  CAS Medical Systems, ... medical devices for non-invasive patient monitoring, today announced that ... Officer,  will present at the 2 nd Annual Marcum ... Hyatt Hotel in New York City . ... p.m. ET in the Estate 10 room and will be ...
(Date:5/23/2013)... 2013 EarlySense, the market leader ... prize for ,Best Novel Idea, at the 8 th ... International Conference, hosted this year in the UK by ... clinical research team studying the impact of the EarlySense ... Los Angeles . The prize was awarded ...
(Date:5/23/2013)... 2013  Inhibikase Therapeutics, Inc., an emerging leader ... will present new results on its antiviral program ... by the PML Consortium (composed of Pfizer, Bristol-Meyers ... is the causative agent of Progressive Multifocal Leukoencephalopathy ... an extended release formulation, can clear JC polyomavirus ...
Breaking Medicine Technology:CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 2Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 3Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 4Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2
... Dual EGFR / HER2 Tyrosine Kinase Inhibitor, Suggests Activity ... Mutations - (1,2)-The First Presentation of Data on BIBF ... Ingelheim will present new data on the company,s two ... the 2009 Annual Meeting of the American Society of ...
... TYRX, Inc., a leader in the ... the 30th Annual Scientific Sessions of the Heart ... its AIGISRX(TM) Antibacterial Envelope Retrospective Registry.AIGIS is an ... that help provide protection against infections associated with ...
Cached Medicine Technology:Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 2Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 3Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 4Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 5Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 6Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 7Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 8Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 9Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 10TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 2TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 3TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 4TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 5TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 6
(Date:5/23/2013)... The Rottenstein Law Group LLP, a New York-based nationwide ... Information Center at http://www.rotlaw.com/tylenol , dedicated to issues ... considering filing lawsuits. , The painkiller Tylenol (acetaminophen) ... according to a 2009 report from the U.S. Food ... FDA warned consumers against using more than the recommended ...
(Date:5/23/2013)... Washington, DC (PRWEB) May 23, 2013 ... have a great deal of control over their level ... their weight, yet far fewer are actually taking that ... International Food Information Council (IFIC) Foundation’s 2013 Food & ... of respondents say it’s possible to have “a great ...
(Date:5/23/2013)... IL (PRWEB) May 23, 2013 Jeanne ... fifth anniversary of its popular and only free OCD ... a successful continuing resource for OCD sufferers, the group ... OCD, and related disorders. This allows group participants ... and Exposure and Response Prevention. , “Participants in Beyond ...
(Date:5/23/2013)... May 23 (HealthDay News) -- Schools should ensure ... physical activity each day to support their health ... new report. Although previous studies show ... promotes health and development, it,s estimated that only ... meeting this recommendation, according to the report from ...
(Date:5/23/2013)... Reporter , , THURSDAY, May 23 (HealthDay News) -- Heavy ... as methamphetamine or crack cocaine, a new study contends. ... or ,coke mouth, it is startling to see the ... same," said Dr. Mohamed Bassiouny, a professor of restorative ... Philadelphia. Methamphetamine, crack cocaine and soda -- sweetened ...
Breaking Medicine News(10 mins):Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2Health News:U.S. School Kids Should Get Hour of Exercise Daily: Report 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 3
... SHANGHAI, Sept. 10 /PRNewswire-Asia/ -- ... announced that Dr. Ge Li, the Company,s Chairman and ... Healthcare,Unplugged Conference in New York on Tuesday, September 15, ... present at the Bank of America Merrill,Lynch Global Healthcare ...
... 9 Family Research Council President Tony Perkins made the ... joint session of Congress. , , ... Tomorrow night in a live webcast at frcaction.org, ... Perkins will be joined by Senator Jim DeMint (R-SC), House ...
... , , MANASSAS, Va., Sept. 9 , ... of ConservativeHQ.com, regarding President Obama,s speech on health care legislation: ... far-left agenda by re-launching an effort for government-run health care. ... Obama is re-launching the conservative movement. , , ...
... , , , ... no meaningful health care reform , , ... Congress Wednesday evening, USAction President William McNary called on Congress to ... companies - and pass quality, affordable health care reform with a ...
... , OAKLAND, Calif., Sept. 9 ... "Technologies for Home and Community-Based Services: Considering the Options," at ... the City Center Marriott Hotel in Oakland on Friday, September 11, ... Lindeman, Ph.D.; Lynn Redington, Dr.PH., M.B.A.; and Valerie Steinmetz. They will ...
... action of nitrogen-containing bisphosphonate (N-BP) cancer drugs, used to ... bone metastasis, has been almost entirely unknown. Researchers writing ... have used ,barcoded, yeast mutants to identify new ... opening up opportunities for the development of new anticancer ...
Cached Medicine News:Health News:WuXi PharmaTech to Participate in Upcoming Investor Conferences 2Health News:President Obama's Campaign Style Speech Points to a Health Care Plan on Life Support 2Health News:Richard Viguerie: Obamacare is Restarting the Conservative Movement 2Health News:Technologies That Redefine Care for Older Americans to be Focus of Conference Session Led by Center for Technology and Aging 2
... The G-4 goniolaser lens features 4 precisely ... 360° view of the anterior chamber angle ... design (flanged glass contact element) provides a ... segment. 4 mirror lens provides ...
The Mid Field 30° lens has a bi-concave design to provide a wider field of view with a 30 degree offset image....
... The Chalam 45° Prism ... pathologies and are recommended for ... etc.) and Rhegmatogenus retinal detachment. ... panretinal photocoagulation and other midperipheral ...
... High-Mag 1.5x is specifically designed ... in macular hole surgery, optic ... membrane removal, traditional macular edema ... magnification. This lens was developed ...
Medicine Products: